Regeneron (REGN) Stock Drops 11% as Melanoma Drug Fails to Topple Merck's Keytruda
18 May 2026 · 12:13 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
Regeneron's experimental melanoma drug fianlimab failed to meet its primary endpoint in a Phase 3 clinical trial against Merck's Keytruda. The combination of fianlimab and Libtayo did not demonstrate statistically significant improvement in progression-free survival. Following the announcement, REGN stock dropped 11% in premarket trading to $618. Multiple Wall Street analysts subsequently cut their price targets on the stock.
Why it matters
Regeneron is a traditional pharmaceutical company; fianlimab is a cancer immunotherapy drug. The clinical trial failure is relevant only to equity market participants with pharma exposure. Cryptocurrency markets are driven by blockchain adoption, regulatory developments, macro monetary policy, and digital asset-specific news—none of which are addressed in this article. While systemic market stress could theoretically reduce risk appetite across asset classes, a single stock decline in the biotech sector is an insufficient trigger. Confidence in any crypto market impact is very low. This article appears misplaced on a crypto news outlet and does not provide actionable intelligence for cryptocurrency investors.
Expected impact
This article reports on Regeneron's failed Phase 3 clinical trial for a melanoma drug and the resulting 11% stock price decline. The story is entirely focused on traditional pharmaceutical and equity markets with no direct connection to cryptocurrency. While cryptocurrency traders sometimes respond to broader market risk sentiment changes, this company-specific biotech failure has minimal mechanism for affecting digital asset prices. Any potential spillover would be indirect and negligible—confined to minor risk-off sentiment if broader equity market weakness ensues, but such effects are typically short-lived and disconnected from crypto fundamentals.